JenaValve Technology
Medical device company developing transcatheter heart valve systems for aortic regurgitation and aortic stenosis, featuring unique clip-based anchoring technology for both indications.
Notes
JenaValve Technology is a medical device company developing transcatheter aortic valve replacement (TAVR) systems. The company's Trilogy Heart Valve System features a unique anatomical anchoring mechanism using clips that attach to the native valve leaflets, enabling treatment of both aortic stenosis and aortic regurgitation.
While other TAVR devices are approved primarily for aortic stenosis, JenaValve's technology is particularly noteworthy for its ability to treat aortic regurgitation, a condition where the aortic valve leaks backward. Aortic regurgitation patients have historically had limited transcatheter options.
The company received CE Mark approval in Europe and has advanced through clinical trials in the United States seeking FDA approval.
Team
- Jeff Krolik - CEO
- Experienced team in cardiovascular device development
Additional Research Findings
- Founded in 2006, headquartered in Irvine, California
- Trilogy Heart Valve System
- Unique clip-based anatomical anchoring
- Treats both aortic stenosis AND aortic regurgitation
- CE Mark approved in Europe
- US clinical trials for FDA approval ongoing
- German origins (Jena, Germany) with US headquarters
- Backed by major medical device investors
- Competes with Edwards Lifesciences, Medtronic, Abbott